We don't hand you a database and wish you luck. Every asset we surface comes scored across eight dimensions, pre-screened for EU JCA readiness and US AMCP / payer-value readiness, and de-risked before it reaches your deal committee. The result: shorter diligence cycles, fewer surprises, sharper offers.
Four ways to engage
Replaces five vendors with one team: subscription database, conference scout, KOL network, diligence consultant, and deal facilitator. Calibrated to one geography of your choice.
A year-long retainer that turns in-licensing into a rigorous, repeatable committee process. Every two months we deliver a fresh cohort of pre-qualified assets — AI-enriched, scored across 9 scientific domains, and validated by your internal committee in a blinded Delphi review inside our private client portal.
Sharply scoped, deck-aligned shortlists for a single corporate-development thesis — EU commercialization-ready, China-origin pipeline, rare-disease bolt-ons. Deterministic scoring + live web enrichment per asset.
Pre-event target lists, counterpart dossiers, scheduled meetings, and structured follow-up. For BIO International, BIO-Europe, ChinaBio, CPHI, JPM, and beyond. We are on the ground — so your BD team meets only qualified counterparties.
Why our shortlists win
Other BD partners hand you a list. We hand you a list that has already survived the evidence reviewer, the JCA assessor, and the payer committee — at least on paper.
Clinical, regulatory, IP, competitive, commercial, strategic fit, deal readiness, and risk. Same yardstick on every dossier.
Every in-scope oncology, ATMP, or cell & gene asset is pre-screened for EU Joint Clinical Assessment readiness. You see the payer story before you bid.
For US-bound assets: AMCP dossier readiness, ICER signal, RWE plan, and likely payer objections — surfaced at diligence stage, not after.
Continuously refreshed from 12+ global conferences per year. What you read today is current — not a snapshot from a quarterly data dump.
JCA went live on 12 January 2025 for all new oncology medicines and advanced therapy medicinal products in the EU. From 2028 it expands to orphan drugs; from 2030 to every centrally authorized product. Pharma BD teams that price JCA risk into diligence today are buying assets others will overpay for in eighteen months. We've already built that lens.
One geography. One thesis. We will scope a 12-month programme or a one-off shortlist — whichever fits your in-licensing rhythm.
Request a tailored proposalNo commitment · Honest fit assessment